1. P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549). (9th September 2021) Authors: Goplen, D; Rahman, M A; Arnesen, V S; Brekke, J; Simonsen, A; Andreas, W; Marienhagen, K; Oltedal, L; Haasz, J; Miletic, H; Solheim, T S; Brandal, P; Lie, S A; Chekenya, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P14.65 Survival in a consecutive series of 467 glioblastoma patients: impact of prognostic factors and recurrent treatment at two independent institutions. (9th September 2021) Authors: Blakstad, H; Brekke, J; Rahman, M A; Arnesen, V S; Brandal, P; Lie, S A; Chekenya, M; Goplen, D Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (6th September 2019) Authors: Preusser, M; Silvani, A; Le Rhun, E; Soffietti, R; Lombardi, G; Sepulveda, J; Brandal, P; Beaney, R; Bonneville-Levard, A; Lorgis, V; Bromberg, J; Erridge, S; Cameron, A; Marosi, C; Golfinopoulos, V; Gorlia, T; Weller, M; Wick, W Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗